The Translational Breast Cancer Research Consortium was well represented at the 2015 ASCO Meeting.  Presentations included:

DNA methylation in serum as an independent marker of outcome and treatment response in TBCRC 005: A prospective study in metastatic breast cancer (MBC) patients; Abstract # 518

TBCRC 010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid (ZA) for the Treatment of Breast Cancer Bone Metastasis (MBC-bone); Abstract # 11080

TBCRC 015: Clinical Evaluation of Germline Genetic Polymorphisms Associated With Capecitabine Toxicity in Patients with Metastatic Breast Cancer; Abstract # 1049